TCGA-78-7160-01A-11R-2039-07
— · cohortA4
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA4
- subtype
- cohortA4
- age_years
- 61
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- COMPLEMENT+0.400
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.390
- ALLOGRAFT_REJECTION+0.380
- KRAS_SIGNALING_UP+0.370
- UV_RESPONSE_DN+0.370
- ANDROGEN_RESPONSE+0.360
- INFLAMMATORY_RESPONSE+0.350
- PROTEIN_SECRETION+0.350
- TGF_BETA_SIGNALING+0.340
- INTERFERON_GAMMA_RESPONSE+0.330
Top 10 suppressed
- E2F_TARGETS-0.420
- DNA_REPAIR-0.410
- MYC_TARGETS_V2-0.370
- MYC_TARGETS_V1-0.300
- G2M_CHECKPOINT-0.210
- PANCREAS_BETA_CELLS-0.170
- SPERMATOGENESIS-0.150
- MTORC1_SIGNALING-0.130
- OXIDATIVE_PHOSPHORYLATION-0.130
- CHOLESTEROL_HOMEOSTASIS-0.120
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0C3-01A-21R-A12P-07 | — | A | 0.861 |
| 2 | TCGA-44-6145-01A-11R-1755-07 | — | cohortA1 | 0.856 |
| 3 | TCGA-AO-A0JF-01A-11R-A056-07 | — | A | 0.855 |
| 4 | TCGA-A7-A0CG-01A-12R-A056-07 | — | A | 0.854 |
| 5 | 653522fe-3289-4e1f-9373-c81f923893a3 | — | — | 0.849 |
| 6 | TCGA-AC-A2B8-01A-11R-A17B-07 | — | A | 0.849 |
| 7 | BS_MY9D8XZ1 | pilocytic astrocytoma | — | 0.846 |
| 8 | TCGA-DK-A1AF-01A-11R-A13Y-07 | — | — | 0.844 |
| 9 | BS_V0Q1G94N | low-grade glioma | — | 0.843 |
| 10 | BS_F8N6CFQE | low-grade glioma | — | 0.837 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 35 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| COMPLEMENT | 0.400 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.390 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.370 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.370 | Inavolisib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.350 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.350 | Remibrutinib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.330 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.290 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.290 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| COAGULATION | 0.270 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.270 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.250 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.240 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |